Literature DB >> 33948669

Menopausal osteoporosis: screening, prevention and treatment.

Eu-Leong Yong1,2, Susan Logan1,2.   

Abstract

Screening for osteoporosis in women can be based on age and weight, using the Osteoporosis Screening Tool for Asians and assessment for other risk factors such as early menopause, Chinese ethnicity and other secondary factors. Based on the resulting risk profile, women can be triaged to dual-energy X-ray absorptiometry (DEXA) scanning for definite diagnosis of osteoporosis. Treatment should be considered in women with previous fragility fractures, DEXA-diagnosed osteoporosis and high risk of fracture. Exercise improves muscle function, can help prevent falls and has moderate effects on improvements in bone mass. Women should ensure adequate calcium intake and vitamin D. Menopausal hormone therapy (MHT) effectively prevents osteoporosis and fractures, and should be encouraged in those aged < 50 years. For women aged < 60 years, MHT or tibolone can be considered, especially if they have vasomotor or genitourinary symptoms. Risedronate or bisphosphonates may then be reserved for those aged over 60 years. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  menopause; osteoporosis; prevention; screening; treatment

Mesh:

Substances:

Year:  2021        PMID: 33948669      PMCID: PMC8801823          DOI: 10.11622/smedj.2021036

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  53 in total

Review 1.  Prevention and treatment of postmenopausal osteoporosis.

Authors:  Sri Harsha Tella; J Christopher Gallagher
Journal:  J Steroid Biochem Mol Biol       Date:  2013-10-29       Impact factor: 4.292

Review 2.  Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors:  Meera Viswanathan; Shivani Reddy; Nancy Berkman; Katie Cullen; Jennifer Cook Middleton; Wanda K Nicholson; Leila C Kahwati
Journal:  JAMA       Date:  2018-06-26       Impact factor: 56.272

3.  Number, Location, and Time Since Prior Fracture as Predictors of Future Fracture in the Elderly From the General Population.

Authors:  Claudia Beaudoin; Sonia Jean; Lynne Moore; Philippe Gamache; Louis Bessette; Louis-Georges Ste-Marie; Jacques P Brown
Journal:  J Bone Miner Res       Date:  2018-06-29       Impact factor: 6.741

Review 4.  Clinical Practice. Postmenopausal Osteoporosis.

Authors:  Dennis M Black; Clifford J Rosen
Journal:  N Engl J Med       Date:  2016-01-21       Impact factor: 91.245

5.  Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density.

Authors:  E Lydick; K Cook; J Turpin; M Melton; R Stine; C Byrnes
Journal:  Am J Manag Care       Date:  1998-01       Impact factor: 2.229

6.  A simple tool to identify asian women at increased risk of osteoporosis.

Authors:  L K Koh; W B Sedrine; T P Torralba; A Kung; S Fujiwara; S P Chan; Q R Huang; R Rajatanavin; K S Tsai; H M Park; J Y Reginster
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

7.  Menopausal hormone therapy and risk of endometrial cancer.

Authors:  Louise A Brinton; Ashley S Felix
Journal:  J Steroid Biochem Mol Biol       Date:  2013-05-13       Impact factor: 4.292

8.  Predictors of circulating vitamin D levels in healthy mid-life Singaporean women.

Authors:  Wei Fun Cheong; Shanshan Ji; Amaury Cazenave-Gassiot; Win Pa Pa Thu; Susan Logan; Jane Cauley; Michael S Kramer; Eu-Leong Yong
Journal:  Arch Osteoporos       Date:  2021-02-09       Impact factor: 2.617

Review 9.  Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

Authors:  Peyman Hadji; Matti S Aapro; Jean-Jacques Body; Michael Gnant; Maria Luisa Brandi; Jean Yves Reginster; M Carola Zillikens; Claus-C Glüer; Tobie de Villiers; Rod Baber; G David Roodman; Cyrus Cooper; Bente Langdahl; Santiago Palacios; John Kanis; Nasser Al-Daghri; Xavier Nogues; Erik Fink Eriksen; Andreas Kurth; Rene Rizzoli; Robert E Coleman
Journal:  J Bone Oncol       Date:  2017-03-23       Impact factor: 4.072

10.  Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women.

Authors:  M Chandran; G Ganesan; K B Tan; J-Y Reginster; M Hiligsmann
Journal:  Osteoporos Int       Date:  2020-08-14       Impact factor: 4.507

View more
  5 in total

1.  Effect of Rhizoma Drynariae on differential gene expression in ovariectomized rats with osteoporosis based on transcriptome sequencing.

Authors:  Hui Su; Haipeng Xue; Shang Gao; Binghan Yan; Ruochong Wang; Guoqing Tan; Zhanwang Xu; Lingfeng Zeng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-02       Impact factor: 6.055

2.  LncRNA BC083743 Silencing Exacerbated Osteoporosis by Regulating the miR-103-3p/SATB2 Axis to Inhibit Osteogenic Differentiation.

Authors:  Feng Lu; Ling Tang
Journal:  Comput Intell Neurosci       Date:  2022-06-20

3.  Coping Strategies Preferred by Patients Treated for Osteoporosis and Analysis of the Difficulties Resulting from the Disease.

Authors:  Agnieszka Barańska; Urszula Religioni; Anna Kłak; Piotr Merks; Magdalena Bogdan; Ewelina Firlej; Anna Sokołowska; Wioleta Kowalska; Bartłomiej Drop
Journal:  Int J Environ Res Public Health       Date:  2022-05-06       Impact factor: 4.614

4.  Osteogenic Differentiation of Human Umbilical Cord Blood Mesenchymal Stem Cells Induced by Liu's Zhenggudan No. 2 Formula.

Authors:  Qiaosong Deng; Shengru Wang; Zheyi Dai; Xiaojun Li; Guanshen Li; Ziheng Wang; Jianfeng Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-06       Impact factor: 2.650

5.  Reduced Circulating Levels of miR-491-5p and miR-485-3p Are Associated with the Occurrence of Vertebral Fractures in Postmenopausal Women with Osteoporosis.

Authors:  Jixi Xu; Mingbo Li; Wei Pei; Jinyong Ding; Yueran Pan; Huifeng Peng; Shiman Lin; Yanbo Huang
Journal:  Genet Res (Camb)       Date:  2022-03-07       Impact factor: 1.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.